OpenCharities

This text was generated using OCR and may contain errors. Check the original PDF to see the document submitted to the regulator.

2025-12-31-accounts

Docusign Envelope ID: D003D46E-53BD-83B4-8197-501AA7B480EA

Charity Registration No. 1183890 (England and Wales) Charity Registration No. SC049802 (Scotland) Company Registration No. 11911752 (England and Wales)

LEUKAEMIA CARE

ANNUAL REPORT AND FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2025

www.leukaemiacare.org.uk

Docusign Envelope ID: D003D46E-53BD-83B4-8197-501AA7B480EA

LEUKAEMIA CARE

LEGAL AND ADMINISTRATIVE INFORMATION

Patrons Lady Penny Mountbatten Beverley Warboys Katie Seymour Chris Seymour Ambassadors Adam Hill Olivia Bromley Dr Amir Khan Andrew Hayden-Smith Trustees Mr Christopher R. G. Matthews Maxwell (Chair) Mrs W J Davies (Treasurer) Mrs Elizabeth Wilson (Vice Chair) Mr Robert Heppell Mr Dharmesh Mehta Ms Carina Patterson Dr Sarah Searle Dr Suzanne Dilly (Appointed 25 June 2025) Mr Peter Mobbs (Appointed 14 November 2025) Dr Luca Sabia (Appointed 19 January 2026) Vice Presidents Ms Sue Merchant Mr Roland Maturi Professor Claire Harrison Dr Robert Marcus Professor Antonio Pagliuca Ms Sheila Hegarty Mr Jason Eliadis Mr C.R.G. Matthews-Maxwell Mr Peter Mondon Mr Anthony Gavin Senior Management Team Chief Executive Officer Colin Dyer Chief Operating Officer and Deputy CEO Monica Izmajlowicz Director of Patient Services Jo Peplow Director of Engagement Nicole Scully Medical Advisory Panels As descibed in the Trustees' Report Secretary Monica Izmajlowicz Charity number (England and Wales) 1183890 Charity number (Scotland) SC049802 Company number 11911752 Website www.leukaemiacare.org.uk

Docusign Envelope ID: D003D46E-53BD-83B4-8197-501AA7B480EA

LEUKAEMIA CARE

LEGAL AND ADMINISTRATIVE INFORMATION

Registered office One Birch Court
Blackpole East
Worcester
WR3 8SG
Auditor Kendall Wadley LLP
Granta Lodge
71 Graham Road
Malvern
Worcestershire
WR14 2JS
Bankers Barclays Bank Plc
54 High Street
Worcester
WR1 2QQ
Solicitors Harrison Clark Rickerbys
5 Deansway
Worcester
WR1 2JG
Investment advisors Titan Wealth Management Limited
2 Greengate
Cardale Park
Harrogate
HG3 1GY
CCLA
Senator house
85 Queen Victoria Street
London
EC4V 4ET
Brewin Dolphin
12 Smithfield Street
London
EC1A 9BD

Docusign Envelope ID: D003D46E-53BD-83B4-8197-501AA7B480EA

LEUKAEMIA CARE

CONTENTS

Page
Trustees' report 1 - 18
Statement of Trustees' responsibilities 19
Independent auditor's report 20 - 22
Statement of financial activities 23 - 24
Balance sheet 25
Statement of cash flows 26
Notes to the financial statements 27 - 45

Docusign Envelope ID: D003D46E-53BD-83B4-8197-501AA7B480EA

LEUKAEMIA CARE

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) FOR THE YEAR ENDED 31 DECEMBER 2025

The Trustees present their annual report and financial statements for the year ended 31 December 2025.

The financial statements have been prepared in accordance with the accounting policies set out in note 1 to the financial statements and comply with the Charity's Memorandum and Articles of Association, the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005, the Charities Accounts (Scotland) Regulations 2006 (as amended) and "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019)".

Objectives and activities

About us

Leukaemia Care is dedicated to ensuring that everyone affected by leukaemia receives the best possible diagnosis, information, advice, treatment and support. We are here for everyone affected by leukaemia and related blood cancer types – such as myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPN).

Purpose

The charity’s objects are set out in its Articles of Association:

  1. The relief of sickness and the promotion and protection of good health among persons suffering from leukaemia and allied blood disorders.

  2. The relief of need among families, carer's and friends of persons suffering from leukaemia and allied blood disorders, and in particular those contemplating or suffering bereavement or who must contemplate the prospect of treatment where those needs are attributable to the affliction of leukaemia and allied blood disorders.

Our vision - our long-term ideal

A future where everyone affected by leukaemia, MDS and MPN gets the best possible diagnosis, information, advice, treatment and support.

Our mission - What we are doing to make that vision a reality

We exist to improve the lives of everyone affected by leukaemia, MDS and MPN.

We provide information, advice and support for anyone affected, this includes patients and their friends and families. We raise awareness of the issues impacting people affected by leukaemia, MDS and MPN, and campaign to fix them. We are driving early diagnosis, raising public awareness, improving services, and ensuring access to effective treatments.

Why our work is important

Source CRUK

Docusign Envelope ID: D003D46E-53BD-83B4-8197-501AA7B480EA

LEUKAEMIA CARE

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2025

Our Strategic Goals

Our organisational strategy sets five clear goals for our work:

  1. Improving diagnosis – through awareness and early detection.

  2. Ensuring everyone receives high quality information, advice and support.

  3. Tackling issues that impact people’s lives.

  4. Advancing treatment and care.

  5. Creating a narrative to better reflect the reality people experience.

For more information on our five goals, please visit our website www.leukaemiacare.org.uk

Public benefit

Leukaemia Care provides public benefit as a charity by providing charitable information, advice and support services to those affected by leukaemia. The Trustees have complied with their duty in accordance with the Charities Act 2011 to have due regard to the Charity Commission’s guidance when reviewing the charity’s aims and objectives, approving funding for projects and services, and in planning and undertaking current and future activities. Taking the Charity Commission’s guidance into consideration, the Trustees are satisfied that our public benefit requirements have been met.

Our work provides information, advice and direct support to anyone affected by a leukaemia, myeloproliferative neoplasm or myelodysplastic syndrome diagnosis; patients, family members, friends as well as employers and schools seeking advice on how best to support employees and students. This information and support help people to live better with their health condition by reducing the isolation that can come with a blood cancer diagnosis, clarity on their treatment options and improving quality of life with strategies to reduce the impact of the side effects of treatment.

Our Spot Leukaemia campaign reaches a wider audience, equipping people with awareness of the common signs and symptoms of leukaemia. This empowers them to discuss with their GP if they have any concerns and increases the likelihood of earlier diagnosis and effective treatment.

Our training raises awareness of the signs and symptoms of leukaemia among GPs and other key healthcare professionals, increasing the likelihood of earlier diagnosis and effective treatment.

Achievements and performance

Executive summary

We saw continued high demand for Leukaemia Care’s information and support services across most areas in 2025 as shown in the Charitable Programmes Summary below, and we continued to develop the charity’s structure to ensure we were able to fulfil that demand in the best possible way. That included the appointments of new roles within data management and governance to ensure good policies and procedures are embedded across the organisation.

We have continued our commitment to improving our governance framework by fully adopting the principles of the Charity Governance Code with its enhanced focus on culture, equity and behaviour, and we have strengthened the Board with two new appointments during the year and one in early 2026 following a skills audit.

A great deal of work has taken place alongside our community to evaluate the charity’s brand and messaging, and to develop a new identity which will be launched in 2026 to help further increase our reach. Also, thanks to grant funding specifically for the project work that has taken place to re-design and refresh the charity’s website and to add some new tools designed to make our information easier to find and understand – with accessibility guiding this work.

Our headquarters has also undergone a much-needed refresh this year to ensure our offices are a welcoming, creative, and environmentally friendly place, and new tenants have moved into the first-floor space which was underused and now provides additional income for the charity.

Docusign Envelope ID: D003D46E-53BD-83B4-8197-501AA7B480EA

LEUKAEMIA CARE

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2025

Charitable Programmes Summary

A breakdown of achievements against our five organisational goals is available in our Strategic Update section below. All funds assigned to Leukaemia Care’s charitable services during the year were consistent with the goals set out in our The Future We Will Create Together strategy (published in 2022). Examples of the allocation of those funds and the continuing increase in demand for our programmes include:

• 921 people were supported by our Patient Navigators in 19 hospitals – with a total of more than 2,500 appointments taking place during the year. This service saw an increase of 36% when compared to 2024.

• We continued to increase the quality and quantity of our PIF (Patient Information Forum) accredited information with 45 new or updated booklets, leaflets and fact sheets produced, and a 38% increase in hard copy orders.

• The charity’s experienced blood cancer nurses and the team answered 1,215 calls to our Helpline and held 607 WhatsApp support conversations with patients and families.

• Our Welfare and Advocacy services grew by around 25% during the year. 465 patients accessed support through our Welfare team receiving help and guidance on a range of topics including benefits applications, financial help, and Blue Badge requests. While 145 patients were supported by our Advocacy service as they reached out for help in areas such as understanding their rights at work or their rights to appeals and second opinions.

• There was a 95% increase in attendance at our peer-to-peer Support Groups, with 692 people taking part in 103 group meetings – 23 of which included an expert speaker to answer key questions.

• Further peer-to-peer support was delivered through our online Facebook Groups which saw numbers increase to almost 3,000, and through our Buddy Service which matched 106 patients with a buddy to give one-to-one support from someone who has lived experience of blood cancer.

• We continued to raise awareness of the signs and symptoms of leukaemia with our Spot Leukaemia campaign running twice during the year. Online, we generated 5.9 million impressions and more than 160,000 website visits. New additions for the year included bus-stop and billboard advertising across the UK.

• 65% of the charity’s expenditure was allocated to our charitable services and projects in 2025 (60% in 2024).

Financial summary

• The total income raised during the year was £2,496,795 (£2,821,699 in 2024) with a total expenditure of £2,448,797 (£2,161,369 in 2024).

• £707,375 of the charity’s income during the year came from legacy donations – including one large legacy of

£250,000.

• The cost of raising funds during the year was £3,039 lower than in the previous year.

• The charity’s total assets at the end of 2025 stood at £3,295,392. This includes £193,150 of restricted funds, £1,247,757 of designated funds, and £1,854,485 of general unrestricted funds (reserves). This is consistent with the charity’s Reserves Policy.

Docusign Envelope ID: D003D46E-53BD-83B4-8197-501AA7B480EA

LEUKAEMIA CARE

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2025

Strategic update for 2025 including our plans for 2026

We exist to improve the lives of everyone affected by leukaemia, MDS and MPN. We are committed to creating a future where everyone affected by leukaemia, MDS and MPN gets the best possible diagnosis, information, advice, treatment and support.

Our organisational strategy focuses on five clear goals for our work. This report sets out Leukaemia Care’s achievements in each of these priority areas during 2025, along with the charity's goals for the year ahead.

1. Improving diagnosis – through awareness and early detection

Our early diagnosis awareness-raising includes our Spot Leukaemia campaign, messaging around awareness days such as World Leukemia Day, our work to influence policy affecting those diagnosed with leukaemia at local and national level, and through our education work with GPs and other healthcare professionals.

In 2025, we ran our Spot Leukaemia awareness campaign through our own channels and through wider online and outdoor display advertising. Online, we generated 5.9 million impressions and more than 160,000 website visits. New additions for the year included bus-stop and billboard advertising across the UK donated by JC Decaux, and the use of podcast advertising played on 854 podcasts receiving 362,000 impressions. The campaign also had more than 120 pieces of press coverage.

Our case for system-wide improvements to blood testing was strengthened when the Royal College of GPs supported our policy call for increased investment in blood testing to match National Institute for Health and Care Excellence (NICE) guidelines. Thanks to our awareness raising activities in Scotland the previous year, we also contributed to the refresh of the Scottish Referral Guidelines for blood cancers which ensures GPs in Scotland have clearer advice on how and when to investigate symptoms of leukaemia, increasing the likelihood they will test patients with symptoms urgently.

Educational materials for GPs continue to be hosted by NHS-funded resource Gateway C and the Royal College of GPs. Gateway C has continued to grow its reach across the GP community, and it has become apparent it is the main route by which to inform GPs about leukaemia. In 2025, in addition to highlighting the courses GPs could take, we provided patient case studies to include in Gateway C’s newsletter.

In 2026, we will continue to focus our Spot Leukaemia campaign on messages and channels which maximise the chances of behaviour change in those people with symptoms. We will also continue to push for a deeper understanding of the presentation of leukaemia, in order that GPs and others involved in diagnosis can more quickly and more easily spot those who have the condition.

2. Ensuring everyone receives high quality information, advice and support

High quality information, advice and support is key for people diagnosed and living with leukaemia, and those around them. This area of work covers our core direct services for patients and their carers and families including our written information (hard copy and online), advice service (incorporating the Helpline, WhatsApp, and email), advocacy casework and welfare advice, Navigators in our Hospital Hubs, support groups and forums, one-to-one buddy support, financial grants, and counselling.

During 2025, we published 45 new or updated webpages, booklets, leaflets or factsheets. Accessibility has been our core focus with 98% of our resources meeting our target reading score. Patient involvement has also been key, and we have used focus groups, surveys, formal review and feedback to help ensure we use suitable language, format and layout for each resource.

Throughout 2025, we received orders for 14,811 printed booklets or leaflets (three times higher than the previous year) and we also maintained our PIF-tick accreditation.

In 2025, the Helpline team answered 1,215 calls, providing more than 100,000 minutes of personalised support, information, and a vital listening ear. With the addition of a second nurse, we now offer a fully nurse-led service and are developing a pro-active call-out system to identify patients who would benefit from regular nurse contact. In addition, 600 WhatsApp messages were responded to.

Docusign Envelope ID: D003D46E-53BD-83B4-8197-501AA7B480EA

LEUKAEMIA CARE

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2025

Demand for our Welfare Service grew by 28 per cent in 2025, with 585 people supported through financial grants and help with applications for Blue Badges, PIP, Attendance Allowance, Employment and Support Allowance, Disability Payments, and housing-related support and information. We provided more than £102,000 in small financial grants from our cost-of-living fund, along with a further £5,000 in exceptional hardship grants for people unable to access support from any other source.

In addition, 145 people were supported by our Advocacy team, up from 118 in the previous year. Employment rights and travel insurance made up half of all cases, followed by second opinion requests, reflecting ongoing and systemic challenges for patients. Support for employment issues included tailored letters and meetings, with input from our HR Manager for more complex situations, ensuring patients receive both practical guidance and emotional reassurance.

Linked to that, our counselling fund provided more essential access to specialist emotional support at a time when NHS counselling is often limited or unavailable – with 108 people receiving counselling (up from 84 in 2024), and more than 600 sessions delivered.

2025 also saw major growth for the Hospital Hub Programme, with an expanded network of active Leukaemia Care Navigators and the launch of our first services in Scotland and Northern Ireland. New Navigators were recruited and embedded at key sites including Bristol, Norfolk & Norwich, Belfast and Manchester, while work progressed to reinstate or establish services in Leicester, Worcester, Cardiff and Antrim.

Our 24 current active Hospital Hubs can be found in Antrim Hospital, Belfast Hospital, Good Hope Hospital (West Midlands), Heartlands Hospital (Birmingham), University of Bristol Hospital, Cardiff, Derriford Hospital, (Plymouth), Royal Gwent Hospital, Freeman Hospital Newcastle, Bournemouth Hospital, Southampton General – acute clinic and CLL clinic, Royal Sussex Hospital (Brighton), Leicester, Nottingham Hospital, Norfolk and Norwich Hospital, Great Western Hospital (Swindon), Beatson Hospital (Glasgow), Queen Elizabeth Hospital (Glasgow), Victoria Hospital (Glasgow), St James Hospital (Leeds), The Christie (Manchester), University College London Hospital and Worcester.

Our Navigators provide emotional support, information and advice to patients and their families within haematology departments and hospital wards. In 2025, they supported 921 people (675 in 2024), delivered 2,503 in person appointments (1,039 in 2024), and handled 746 calls (483 in 2024). They also made 1,295 referrals into the charity’s wider services.

In addition, we continued to expand our CAR-T (Chimeric Antigen Receptor) Away from Home service during the year, which was, once again, supported through our partnership with the Dalata Hotels Group. This service provides both financial and accommodation support to help patients (and their families) experiencing this intensive and life-saving treatment which is often provided at hospitals many miles from where patients live. In 2025 we organised a total of 222 nights of accommodation and made 45 grants.

Peer-to-peer support remains a crucial element of the charity’s portfolio of support – and we held 103 support group meetings across 27 groups covering different leukaemias and myeloproliferative neoplasms during the year, supporting 692 people. New support groups were launched in partnership with MDS UK and Southeast London Hospitals for patients with CMML, AML and MDS in London, along with new CLL support groups in Oxford and Bicester with the Oxford CLL haematology team and hospitals trust.

Alongside that, 65 new patients or carers have been paired with a buddy for support, with 30 new buddies trained as we continued to transition from our open-ended buddy programme to a 12-week scheme. We focused on providing existing buddies with refresher training and recruiting new ones (to address gaps in provision for certain conditions). Our successful recruitment has meant our waiting list has reduced significantly. More information is contained in the Volunteers section.

We run five closed Facebook groups (all leukaemias, AML, APL, CLL and loss and bereavement). In 2025, we trained more volunteer moderators, retrained existing moderators and implemented robust guidelines to help them respond to members effectively.

Docusign Envelope ID: D003D46E-53BD-83B4-8197-501AA7B480EA

LEUKAEMIA CARE

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2025

We also plan to continue the development of new materials to meet identified needs including topics such emotions and everyday life with leukaemia, MDS or MPNs.

In addition, we will continue to develop all of our patient support and peer-to-peer services – carrying out in-depth analysis of the clearly increasing demand and examining potential new solutions and systems to increase capacity and resource with our limited funds.

3. Tackling issues that impact people’s lives

Ensuring that Leukaemia Care can understand the issues facing people with leukaemia and those caring for them (both personally and professionally) is essential to our work, allowing us to push where appropriate for improvements in care and support.

In 2025, we were able to give direct input into the Government’s 10-year Cancer Plan which is due to be published in 2026, ensuring that the needs of people affected by leukaemia and other blood cancers have been recognised. We also continued to contribute to campaigns on Safe Sick Pay and responded to Government changes to welfare policy.

We also aligned policy makers, patients, nurses, doctors and charities around a shared definition of good care, which we then published as a charter for patient care. The charter establishes a clear benchmark against which services can assess their provision. It sets out who needs practical, emotional and financial support and the basic setting up of a hospital clinic to best support them. The document was also endorsed by the UK Oncology Nursing Society (UKONS), helping to increase the likelihood the document will be seen by nurses and therefore implemented. UKONS can also support our ambition to improve care by sharing resources with us and partnering on future work.

To ensure we provide the most effective services possible and campaign for change effectively, we continue to prioritise deepening our understanding of the impact of our services on patients and on the health system. We published our impact report focused on our Hospital Hub programme with independent input from students at the University of Oxford – demonstrating a very positive social return on investment in the programme. Our close relationship with umbrella groups such as Cancer52 have afforded us opportunities to share this research with decision makers, and we presented the findings in parliament where NHS leaders were present.

We will also continue to work to join important discussions into 2026, when the Government intends to consult on changes to Personal Independence Payments, and will continue to work on the measurement of our impact, further engaging with the University of Oxford’s Making A Difference programme.

4. Advancing treatment and care

The charity has continued to bring health professionals together to help inform best practice for Leukaemia Care patients, and to engage those professionals in our work to ensure we are providing care and support in the best possible way.

109 medical professionals donated their time during 2025. This included joining our Support Group meetings to answer patient questions and working with our Information Team to add their expertise to new or updated resources.

The charity’s work to ensure the best access to treatment for patients also includes our involvement in relevant Health Technology Appraisals for leukaemia, MDS and MPN. This ensures that patient views when decisions that affect them are being made, in an otherwise highly technical process. We supported 8 of these in 2025.

There were some positive changes in 2025 with the Department of Health announcing they would be willing to pay more for the benefits of treatments. Through supporting the Blood Cancer Alliance to investigate these issues and advocate for change, we have ensured that this issue is kept on the agenda and increase the likelihood that future treatments will be made available in the UK. This work is best done collectively as

Docusign Envelope ID: D003D46E-53BD-83B4-8197-501AA7B480EA

LEUKAEMIA CARE

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2025

issues are shared across the blood cancer community and many voices amplifying shared messages increase the likelihood of change occurring.

Goal 5: Creating a narrative to better reflect the reality people face

In 2025 we strengthened how we communicate the reality of leukaemia. Our aim is that when someone affected by leukaemia hears from Leukaemia Care, they feel understood and can quickly find clear, reliable information and support.

During the year, we began a refresh of our brand, informed by consultation with people who use our services, alongside staff, trustees and members of the public. This work ensures our language and identity reflect the emotional and practical realities of diagnosis, treatment and living with blood cancer.

We also progressed plans for a new website. For many people, our website is their first point of contact with Leukaemia Care, often at a frightening time. It must be accessible, clear and easy to navigate.

Following a review of our printed magazine, Leukaemia Matters , and consultation with readers, the decision was taken to retire the publication and focus resources on communication channels that allow more timely and accessible engagement. We remain committed to ensuring information is available to those who are not digitally connected.

Email continues to play an important role in connecting with supporters and people affected by leukaemia. Our communications maintained strong engagement and directed people to information and support. Awareness-focused emails led to increased contact with our services, showing that clear messaging can prompt help-seeking behaviour.

We secured more than 100 pieces of media coverage across national, regional and broadcast outlets. Much of this focused-on signs and symptoms and the importance of early diagnosis, alongside the psychological impact of diagnosis. By combining personal stories with practical health information, we helped humanise the condition while reinforcing clear public health messages.

Across our social media platforms, we reached more than 1.8 million people. Content focused on symptoms, awareness days and myth-busting was widely shared. Expert-led content helped us reach new audiences and strengthen trust in our information.

In 2025, our communications became clearer, more consistent and more reflective of the people we serve. By ensuring our messaging is compassionate, accurate and accessible, we help people recognise symptoms, seek support and feel less alone.

Fundraising

Leukaemia Care is registered with the Fundraising Regulator and agrees that when fundraising we will do so in accordance with the Fundraising Promise and the new Code of Fundraising Practice which came into effect on 1st November 2025.

We agree to promote the Fundraising Promise (https://www.fundraisingregulator.org.uk/) and to include the Registration Badge on our fundraising materials where practical.

We are committed to protecting vulnerable people and others from unreasonable intrusion on a person’s privacy, unreasonably persistent approaches or undue pressure to give during or in connection with fundraising for Leukaemia Care. As a result, the charity is registered to receive suppressions under the Fundraising Preference Service and will actively promote this service to anyone enquiring directly to the charity about concerns with our fundraising approach.

Docusign Envelope ID: D003D46E-53BD-83B4-8197-501AA7B480EA

LEUKAEMIA CARE

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2025

In 2025, the charity received no suppression requests through the Fundraising Preference Service and no fundraising complaints.

Our current complaints procedure can be found here

2025 was an exceptional year in terms of funds raised by the charity. A total income of £2,496,795 was secured – £431,798 ahead of the year’s target budget.

Much of that increase was due to the generosity of some supporters in leaving legacy donations to the charity – totalling £707,375.

‘Team LC’ in the 2025 London Marathon saw 230 runners cross the finish line raising £799,150, while other challenge event participants added a further £353,353 to our funds.

Staff and customers at the Dalata Hotels Group continued their support throughout 2025, with the company committing to another three-year partnership with Leukaemia Care and raising more than £82,268.

Fundraising support came in all shapes and sizes. Kind donations were received from individuals, many being patients themselves, sending one-off gifts or contributions through campaigns and promotions such as our newly introduced weekly lottery. Additionally, donations from those remembering loved ones, community groups, schools and small businesses raised more than £212,607.

Pharmaceutical grants

Leukaemia Care maintains links with key pharmaceutical companies working in the blood cancer space. This represents a joint effort to ensure that the needs of patients are fully considered during the development of new drugs and treatments. Our patient advisory work plays an important role in making sure treatments are thoroughly appraised and person-centred before they are made available to the public. As a way of helping us remain secure and to continue to be effective in our work with patients, various pharmaceutical companies provide us with funding throughout the year. This funding is always received and dispersed strictly within the guidelines laid down by the Association of the British Pharmaceutical Industry (ABPI) and Leukaemia Care’s own Code of Practice.

To ensure that we remain financially independent, we do not allow the total level of funding received from the pharmaceutical industry to exceed 25% of our total annual income. We also do not allow the funding received from any individual company to exceed 10% of our total annual income,

In 2025, we were grateful for the following support from the pharmaceutical industry, which totalled £127,657.

(Please note that the list below reflects funding that was received into our account during the 2025 financial year. Any funding that was pledged during 2025 but not received until after December will be acknowledged in the Annual Report for 2026. By that same token, there will be funders listed below who made their pledge in 2024, and their payment was received in 2025).

Abbvie - £10,000 for Essential Thrombocythaemia resources

Amgen - £13,000 for Emotional Support resources

Astellas - £5,075 for Early Diagnosis work

Autolus - £10,000 for CAR-T Therapy resources and our Away From Home service

BeOne Medicines – £37,082 for our Nurse Helpline

Johnson & Johnson - £5,000 towards our core expenditure including helpline, support groups and hospital hubs

Kyowa Kirin - £7,500 towards our core expenditure including helpline and support groups (pledged in 2024) + £5,000 for Hospital Hubs

Lilly - £10,000 for corporate membership

Pfizer - £10,000 for our Hospital Hub Network

Takeda - £15,000 towards our core expenditure including helpline, support groups and hospital hubs

Docusign Envelope ID: D003D46E-53BD-83B4-8197-501AA7B480EA

LEUKAEMIA CARE

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2025

Grants and trusts

Leukaemia Care receives no statutory funding, but it does receive grants from trusts and other independent funders. These grants are an increasingly important part of our income and significantly improve our ability to deliver services to leukaemia patients and their families across the UK. We thank the following funders who kindly pledged their support in 2025.

( Please note that the same qualifications apply to the list below as the one above. )

29th May 1961 Charity Marsh Charitable Trust Alice Ellen Cooper Dean Charitable Maud Elkington Charitable Trust Foundation Michael and Anna Wix Charitable Trust Ampa Foundation Miss E C Hendry Charitable Trust Annie Tranmer Charitable Trust N Smith Charitable Settlement Ardwick Trust National Lottery Community Fund England B-C H 1971 Charitable Trust National Lottery Community Fund Northern Ireland Barnard Kenneth Hufton Charity Norie Charitable Trust Burford Trust Patrick Trust Chalk Cliff Trust Roger and Douglas Turner Charitable Trust Colefax Charitable Trust Sandra Charitable Trust Crerar Trust Santa Barbara Heights Charitable Trust David William Traill Cargill Fund Simon Gibson Charitable Trust Enkalon Foundation Sir John Eastwood Foundation Esme Mitchell Trust Souter Charitable Trust Eveson Trust Sovereign Health Care Charitable Trust Fidelity Foundation Strangward Trust Florence Turner Trust Templeton Goodwill Trust Fullagar Charitable Trust W E Dunn Trust Geoff Hill's Charitable Trust Walter Guinness Charitable Trust Gordon Fraser Charitable Trust William Allen Young Charitable Trust Hugh Fraser Foundation Ian Askew Charitable Trust We also received a grant from one further trust J Reginald Corah Foundation Fund which wished to remain anonymous. James T Howat Charitable Trust John James Bristol Foundation Joseph Strong Frazer Trust Leukaemia & Lymphoma NI

Docusign Envelope ID: D003D46E-53BD-83B4-8197-501AA7B480EA

LEUKAEMIA CARE

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2025

Grant making by Leukaemia Care

Leukaemia Care has four grant making streams: the Cost of Living with Leukaemia Fund, the Leukaemia Counselling Fund, the Exceptional Hardship Fund and the CAR-T Away from Home Service.

This fund provides grants of up to £175 for essential living costs to patients and their families affected by leukaemia, myelodysplastic syndrome (MDS) or myeloproliferative neoplasms (MPN). All applicants must provide a copy of a letter from their consultant confirming diagnosis. There is no closing date, awards are distributed on a first-come, first-served basis until the fund is depleted each month.

The Exceptional Hardship Fund provides up to £800 in financial support for people diagnosed with leukaemia, MDS or MPN who are experiencing severe financial difficulty linked to their condition. Applicants must provide proof of diagnosis, evidence of household income and expenditure, and a brief explanation of their hardship. Funding can be used for essential living costs, medical and nonmedical expenses, travel for treatment, childcare, mobility aids, and other needs directly related to the impact of the diagnosis. Applications are assessed by the Senior Management Team, and awards are made on a first-come, firstserved basis.

This fund provides vital emotional and psychological support for patients and their families during a blood cancer diagnosis. Those diagnosed with leukaemia, MDS or MPNs, or the parent, sibling, child or spouse of someone with these conditions can receive up to £420 in funded counselling, paid directly to an approved counsellor. All counsellors must be registered with BACP, UKCP, COSCA, NCPS or PTUK. The fund opens at the start of each year, and awards are made on a first-come, first-served basis until the annual allocation is fully distributed.

The CAR-T Away from Home Service supports patients undergoing CART (Chimeric Antigen Receptor) therapy, a treatment that has transformed care for people with leukaemia but often requires long periods spent near specialist hospitals. Patients can apply for accommodation, a grant, or both, with one grant available per family. The service is open to anyone currently going through CAR-T therapy, and applications can be made as soon as treatment is recommended. Funding is allocated on a first-come, first-served basis. Through our partnership with Dalata Hotels, families can access up to 30 nights of free accommodation in a double or twin room, arranged directly by Leukaemia Care. This cannot be exchanged for money or alternative hotels. In addition, we provide up to £500 in grant funding to help with associated costs such as travel or increased food expenses while away from home.

Volunteers

Our volunteers play a crucial role in ensuring that we provide essential support to individuals affected by leukaemia, MDS, or an MPN. Some volunteers offer direct support to patients and carers, while others contribute by advising our information resources or assisting with fundraising efforts. Each volunteer brings unique experience and value, whether they are a patient, clinician, carer, or supporter and in 2025, 45 new volunteers joined Leukaemia Care.

The Buddy Scheme remains one of our most significant volunteer-led programs, providing one-on-one support to patients and carers from trained volunteers with lived experience of a leukaemia, MDS or MPN diagnosis. In 2025:

Docusign Envelope ID: D003D46E-53BD-83B4-8197-501AA7B480EA

LEUKAEMIA CARE

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2025

Our Patient Advisory Panels are run when Leukaemia Care requires input from patients, family members, carers, and those who have lost loved ones to leukaemia. These panels ensure that lived experience informs the development of our services and resources.

. Patient Information Reviewers

Patient and carer volunteers played a key role in reviewing and updating our information resources in 2025. Their insights ensure that our information remains accurate, accessible, and reflective of patient experience.

Our Facebook support groups continued to be a valuable resource for patients and carers.

Medical Advisors

Healthcare professionals continued to play a vital role in 2025, Key activities included:

Key priorities include:

Docusign Envelope ID: D003D46E-53BD-83B4-8197-501AA7B480EA

LEUKAEMIA CARE

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2025

Risk assessment and management

The Board of Trustees approved an updated Risk Register during the year as part of its ongoing work to ensure compliance with the Charity Governance Code. It is a standing item on the Board's agenda as well as being a living document. Trustees have access through the charities Sharepoint site and can review at any time. With the strengthening of the governance framework, risks are reviewed by their relevant sub-committee, spreading the responsibility for oversight and regular engagement with the Senior Management Team to ensure any risks the charity may face in the forthcoming year are being managed.

Significant progress has been made during the reporting year on risk management with constant review and regular reporting. Key areas monitored are charitable activity, communications, financial management, fundraising, Human Resources, management and governance, new technologies – AI, operations, IT, data and cybersecurity and safeguarding.

Key risks mitigated in 2025.

We have appointed a Data Manager who reviewed our database, and data flows across all activity areas. Recommendations for improvements were implemented by December 2025 and data flow mapping will be updated annually. All policies relating to data were reviewed and updated as necessary. All employees were provided with refresher training in using the Raisers Edge NXT database as well as our project management platform Asana. Training sessions were recorded, and guides were provided for reference. In 2026, we will continue to improve processes and the quality of data held.

We secured Cyber Essentials accreditation in April and will re-accredit in 2026, when we will also evaluate an upgrade to Cyber Essentials Plus to further test the security of our systems. We have also upgraded our antivirus software and will keep this under review.

In anticipation of a widespread adoption of AI tools, we formed an AI Working Group producing a policy and rolling out mandatory training to all employees on the risks of using AI tools and how to mitigate them.

As we expand our Patient Navigator programme in hospitals and other activity areas, we agreed to scale our safeguarding procedures to match. A lead Safeguarding Trustee was appointed who works with the current Designated Safeguarding Lead (the COO) to ensure our policies and procedures are robust. Consequently, we trained Directors and relevant managers across all activity areas as Designated Safeguarding Leads for their areas reporting to the COO.

Implementation of sub-committees for Audit and Finance, Governance, and HR and Remuneration has ensured workload is spread more evenly across the entire Trustee Board. Following a skills audit in winter 2024, the Board advertised and recruited three new Trustees (one Trustee early January 2026) to address the skills gaps identified and to support succession planning. To support the new Trustees, the Trustee training and induction was reviewed prior to their appointments and a Trustee Code of Conduct adopted which all Board members signed.

Continuing to abide by best practice as recommended by the Charity Governance Code, the Board agreed to introduce limited terms of service for Trustees which will come into effect in 2026. All new Trustees will serve two terms of three years with a further term of three years agreed only in exceptional circumstances. Existing Trustees will serve between one and two terms of three years depending on the length of their service to date to support a smooth transition. They also agreed that the offices of Chair, Vice Chair and Treasurer should rotate at three years' service.

As at the date of signing the report, the highest risks recognised on the organisation’s Risk Register are: safeguarding; maintaining the quality of support provided to patients and their families with rising demand; cybersecurity; the lack of a formal agreement between the charity and our trading subsidiary (although dormant); and failing to secure further corporate partnerships to fund our charitable activities. All risks are monitored regularly and mitigation actions identified with a forward looking action plan to address and reduce risks to an acceptable level.

In addition, a full update, financial, and progress report including any identified or potential risks is provided to the Board by the CEO and COO quarterly, allowing Trustees to monitor progress against the charity’s strategic objectives.

Docusign Envelope ID: D003D46E-53BD-83B4-8197-501AA7B480EA

LEUKAEMIA CARE

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2025

The Board of Trustees approves a detailed annual budget at its Autumn meeting (including cashflow and scenario planning), and the regular financial report provided to the Board identifies all changes in forecasts when compared to that budget.

The Trustees are confident that reasonable systems have been established to identify, mitigate, and manage new and existing risks, and that forward planning will enable the charity to be prepared for all future eventualities. Trustee Indemnity insurance of £5,000,000 is in place.

Our Reserves Policy

Leukaemia Care’s Reserves Policy has been developed in line with best practice guidance to maintain resilience within the finances of the charity. By developing an intelligent reserves policy with a clear understanding of income and expenditure, we aim to consider and mitigate financial risk more effectively.

We recognise that money is donated to advance our charitable purposes. As such, our policy is to only hold reserves for a particular objective or to mitigate a particular risk, to avoid tying up money unnecessarily.

Leukaemia Care has a separate Investment Policy which considers the best use of reserves for generating financial return, preserving capital value, and meeting unanticipated cash flow requirements. For the purpose of investment, Leukaemia Care has divided its reserves into two, those expected to be held for a long-term horizon and those that may be needed in the short term.

It is Leukaemia Care’s policy to express reserves in terms of ‘months of expenditure’ for the purposes of external communications.

Our policy identifies five factors requiring the charity to hold reserves. These are considered in the context of both individual risks and by summation (the addition of multiple risks happening at once):

In line with the considerations above, Leukaemia Care’s policy is to hold sufficient funds to cover no less than six months of operating costs or wind-down costs based on the expense of closing Leukaemia Care – whichever is higher.

If Reserves exceed the upper target level, Trustees will consider whether excess should be used for charitable activity, designated for future planned investment, or used to reduce future fundraising burden, ensuring strategic value and alignment with mission. The designated funds reserve (note 23) has been set aside to support the expansion of the charity’s services.

The level of reserves is monitored quarterly by the Head of Finance and in regular Audit and Finance subcommittee meetings. Any deviation below or above the target will trigger a review by Trustees, with appropriate action proposed.

Our policy is subject to annual review by the Board of Trustees, with the reserves also reviewed in line with the policy at the Autumn Board meeting where the following year’s budget is approved. Notwithstanding this, the reserves’ amount is calculable at any point of the year if required, as the financial position of the charity changes or plans alter.

Docusign Envelope ID: D003D46E-53BD-83B4-8197-501AA7B480EA

LEUKAEMIA CARE

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2025

Our Investment Policy

The Trustee Board regularly monitors cash and investments against objectives and risk profile. The Investment Policy is reviewed annually by the Audit and Finance sub-committee, and recommendations made to Board. Day-to-day investment management is delegated to authorised professional investment advisors, regulated by the FCA.

Our Investment Policy aims to produce the best financial return at an acceptable level of risk. The investment objective for the long-term reserves is to generate a return more than inflation over the long term, but also to ‐ be available at short notice to support the on going activities of Leukaemia Care. The objective of investment for the short-term reserves is to maximise returns whilst preserving the capital value with a minimum level of risk. Assets should be readily available to meet unanticipated cash flow requirements.

Leukaemia Care is reliant on fundraising and donations for its activities. Investment assets are held as reserves. The key risk to the long-term reserves is inflation, and the assets should be invested to mitigate this risk over the long term. The Trustees understand that this is likely to mean that investment will be concentrated on real assets and that the capital value will fluctuate. This means the capital value can go down as well as up and the return of the amount invested is not secure.

The short-term reserves are held to provide financial security and may be required at short notice. As such capital volatility cannot be tolerated and investment of these assets should be focused on minimising this.

Due to the nature of the reserves, the Board wishes to keep the majority of cash reserves realisable within 6 months. A minimum of £500k short-term reserves must remain realisable within one month. A maximum of £500k may be invested in term deposits over 6 months but realisable within 12 months.

Income generated from the investments held by the long-term reserves is not required and can be reinvested.

Leukaemia Care has approximately £2m reserves for investment. A portion of these reserves have been identified as long-term reserves invested in the stock market with an appointed investment manager (approx. £700k). Cash balances more than working capital requirements are held in a mix of instant access and term deposit accounts to maximise interest income.

Cash funds are to be invested with Insignis cash platform. Insignis is not a bank; they are an authorised payment institution regulated by the Financial Conduct Authority (FCA). This means they can make secure payments on our instruction and bring together information from the various accounts where your funds are deposited, giving us a complete view of our cash holdings. When we transfer money to our Insignis Account or “Hub”, it is held in a client account with either Barclays or HSBC before being allocated to selected deposit accounts.

Assets are managed under a "bare trust”, this means that we as the beneficiary of the trust, have an absolute right to the capital within it, as well as the income generated from that capital. Once placed with deposit-takers, funds will be subject to FSCS protection subject to the £120,000 limit per eligible depositor, per banking group.

Decisions for investments are made by the Trustee Board where a quorum is necessary to ensure the decision is valid. In certain circumstances it may be beneficial to deviate from the agreed investment policy in respect of amounts invested on the cash platform. These decisions may need to be made between Trustee board meetings. In these situations, the finance and audit sub-committee may discuss and propose approval by other trustees by email. Management of funds invested in real assets will be delegated to an authorised professional investment advisor, regulated by the FCA.

Leukaemia Care has adopted an ethical investment policy to ensure that its investments do not conflict with its aims. There is a proven link between the disease and the consumption of alcohol and tobacco.

Our ethical investment policy therefore precludes direct or indirect investment in companies that generate more than 10% of revenues from alcohol or tobacco.

Docusign Envelope ID: D003D46E-53BD-83B4-8197-501AA7B480EA

LEUKAEMIA CARE

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2025

Structure, Governance and Management

Constitution

Leukaemia Care was incorporated on 28th March 2019 and is registered as a private company limited by guarantee (Registered No: 11911752). It was then registered with the Charity Commission on 13 June 2019 (Registered No: 1183890) and with the Scottish Charity Regulator on 9th December 2019 (Registered No: SCO49802).

Trustee Board responsibilities

The Trustees are responsible for the governance and strategy of the charity. A minimum of five and a maximum of 12 Trustees in office at any one time are required by the constitution, and at the time of writing this report there were 10 Trustees in office. Three sub-committees have been formed and have the appropriate number of Trustees to comply with their Terms of Reference.

At each AGM one-third of the Trustees must retire from office but may stand for re-election. On 5th November 2025, the Trustees agreed to the introduction of limited terms of service for Trustees which will come into effect in 2026. All new Trustees will serve two terms of three years with a further term of three years agreed only in exceptional circumstances. An addendum to the Articles and submission to the Charity Commission, Companies House and the Office of the Scottish Charity Regulator will follow in early 2026. Trustees receive no remuneration for their duties but are entitled to claim reasonable expenses incurred such as travel to trustee meetings and accommodation. The full Trustee Board meets four times a year in addition to the Annual General Meeting in hybrid style of the Trustee’s choice, and delegate day-to-day running of the charity to the senior management team.

The Trustees who served during the year and up to the date of signature of the financial statements were:

Docusign Envelope ID: D003D46E-53BD-83B4-8197-501AA7B480EA

LEUKAEMIA CARE

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2025

Recruitment, induction and training of Trustees

In 2024, the Board carried out a Skills Audit and Board Effectiveness Survey and identified key areas for improvement on the Board. Role specifications were drafted for Trustees with expertise in life sciences/ pharmaceutical industry, finance, and marketing and communications.

These roles were advertised on our social media but also through networks like Reach Volunteering. Potential applicants were invited to submit a CV and if shortlisted for interview, were interviewed by representatives from each sub-committee. Successful applicants were co-opted as Trustees until their formal election at the next AGM.

New Trustees attend an induction at our offices in Worcester with the executive team and identify areas in which they may wish to take a special interest. They are provided with an induction pack including a copy of the constitution, recent Trustee board minutes, accounts, financial reports, the charity’s strategy as well as helpful publications such as the Charity Commissions “The Essential Trustee”. Trustees also complete the free online Trustee training provided by ICAEW which outlines their duties and responsibilities. Any Trustee that takes on a specific role, such as Safeguarding Trustee, is provided with additional training relevant to their specialist role.

The Board appointed two new Trustees in 2025 and a third in 2026 who were co-opted until their formal election at the next AGM.

Our Trading Subsidiary

Ahead of the launch of our art trail Unicornfest which took place in 2023, the Trustees of Leukaemia Care Limited decided to register a trading subsidiary – Leukaemia Care Trading Limited which was registered at Companies House on 21 April 2022 (Registered No: 14059389). Its directors are Chris Matthews-Maxwell, Elizabeth Wilson and Wendy Davies who are also the Chair, Vice Chair and Treasurer of the parent charity, Leukaemia Care Limited. All trading activities relating to Unicornfest went through the subsidiary company. It has not been used for any other purpose since the trail ended in 2023 and remains dormant.

Senior Management Team

The Trustees delegate day-to-day operations of the charity to the executive team.

Chief Executive Officer Colin Dyer Chief Operating Officer & Deputy CEO Monica Izmajlowicz Director of Engagement Nicole Scully Director of Patient Services Jo Peplow

Our Patrons

We are very grateful for the warm support of our patrons, Lady Penny Mountbatten, Beverley Worboys and Katie and Chris Seymour.

Vice Presidents

Ms Sue Merchant Ms Sheila Hegarty Mr Roland Maturi Mr Jason Eliadis Professor Claire Harrison Mr C.R.G. Matthews-Maxwell Dr Robert Marcus Mr Peter Mondon Professor Antonio Pagliuca Mr Anthony Gavin

Following the death of Dr Richard Taylor in 2024, the position of President had remained vacant. At their meeting in June 2025 the trustees agreed that the role of President and Vice Presidents should be discontinued. It was originally established to honour those individuals who had made a significant contribution to the charity either in raising awareness of leukaemia, as healthcare professionals championing patient support and access to treatments, or as long serving and dedicated trustees or CEOs of the charity. The Vice Presidents will be informed to confirm the retirement of their role and to extend the Boards’ thanks for their past service.

Docusign Envelope ID: D003D46E-53BD-83B4-8197-501AA7B480EA

LEUKAEMIA CARE

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2025

Remuneration policy

The Charity is committed to retaining and fairly rewarding all its employees. We therefore recognise the importance of a fair, consistent, and transparent pay and pay review process.

The Board of Trustees are responsible for setting remuneration levels for the senior management team: CEO, COO, Director of Engagement and Director of Patient Services. The CEO has the authority to agree salaries for all employees outside of the senior management team within the guidelines of this policy.

The Charity’s policy is that the highest paid member of staff will not exceed a 3:1 ratio based on the median full-time equivalent salary.

The remuneration policy is reviewed annually by Trustees, normally at their meeting in November. Salaries are reviewed annually in September ahead of budget planning for the following year to determine if there will be a cost-of-living increase. This will be based on:

The Charity is committed to paying a real living wage to all employees at the level set by the Living Wage Fondation (the London weighting does not apply to remote workers). When setting remuneration levels for job roles within Leukaemia Care, we consider the following factors:

In addition, all employees are eligible to an annual pay review with effect from 1 October. This does not mean that all employees are eligible for a pay increase in addition to any cost-of-living increase. This policy is outlined in the separate Annual Salary Review Policy.

As part of our commitment to transparency, information regarding the salary bandings will be made available to all Leukaemia Care staff. The salary bands apply to all roles, unless identified as requiring specific professional qualifications that fall outside this banding. Identified roles may follow other scales, such as the NHS salary scale.

The Board of Trustees is committed to including the following information within its annual statutory report and financial statements:

Docusign Envelope ID: D003D46E-53BD-83B4-8197-501AA7B480EA

LEUKAEMIA CARE

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2025

Pensions

The charity is committed to retaining and fairly rewarding all its employees. A company pension scheme is an important part of a benefits package. In June 2025 we move to a new provider – Aviva, to improve engagement and introduced a salary exchange scheme. Workshops were set up as part of a team day to ensure all employees understood the changes and what they meant for them. Leukaemia Care continues to match any employee contributions up to a maximum of 7% of their qualifying earnings.

Related parties

In addition to the trading subsidiary undertaking, Leukaemia Care Trading Limited, the only related parties are the Trustees and those individuals connected with them including family members, business associates and other charities in which they are involved. A register of interests is kept and updated as notified. Please refer to note 11 in the financial statements for detail.

Auditor

I n line with best practice in the Charity Governance Code, Leukaemia Care will review its audit provision every five years and therefore will be going out to tender for auditors in 2026 to audit the 2026 accounts in 2027. Our current auditors are eligible to re-tender.

Disclosure of information to auditor

Each of the Trustees has confirmed that there is no information of which they are aware that is relevant to the audit, but of which the auditor is unaware. They have further confirmed that they have taken appropriate steps to identify such relevant information and to establish that the auditor is aware of such information.

The report has been prepared having take advantage of the small companies regime in the Companies Act 2006.

The Trustees' report was approved by the Board of Trustees.

Mr Christopher R. G. Matthews Maxwell (Chair)

Trustee Dated: 24 June 2026

Docusign Envelope ID: D003D46E-53BD-83B4-8197-501AA7B480EA

LEUKAEMIA CARE

STATEMENT OF TRUSTEES' RESPONSIBILITIES FOR THE YEAR ENDED 31 DECEMBER 2025

The Trustees, who are also the directors of Leukaemia Care for the purpose of company law, are responsible for preparing the Trustees' Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company law requires the Trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the Charity and of the incoming resources and application of resources, including the income and expenditure, of the charitable company for that year.

In preparing these financial statements, the Trustees are required to:

The Trustees are responsible for keeping adequate accounting records that disclose with reasonable accuracy at any time the financial position of the Charity and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the Charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Docusign Envelope ID: D003D46E-53BD-83B4-8197-501AA7B480EA

LEUKAEMIA CARE

INDEPENDENT AUDITOR'S REPORT TO THE TRUSTEES OF LEUKAEMIA CARE

Opinion

We have audited the financial statements of Leukaemia Care (the ‘Charity’) for the year ended 31 December 2025 which comprise the statement of financial activities, the balance sheet, the statement of cash flows and notes to the financial statements, including significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice).

In our opinion, the financial statements:

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the Charity in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC’s Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the Trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the Charity’s ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the Trustees with respect to going concern are described in the relevant sections of this report.

Other information

The other information comprises the information included in the annual report other than the financial statements and our auditor's report thereon. The Trustees are responsible for the other information contained within the annual report. Our opinion on the financial statements does not cover the other information and we do not express any form of assurance conclusion thereon. Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

Opinons on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of our audit:

Docusign Envelope ID: D003D46E-53BD-83B4-8197-501AA7B480EA

LEUKAEMIA CARE

INDEPENDENT AUDITOR'S REPORT (CONTINUED) TO THE TRUSTEES OF LEUKAEMIA CARE

Matters on which we are required to report by exception

We have nothing to report in respect of the following matters in relation to which the Charities (Accounts and Reports) Regulations 2008 requires us to report to you if, in our opinion:

Responsibilities of Trustees

As explained more fully in the statement of Trustees' responsibilities, the Trustees, who are also the directors of the Charity for the purpose of company law, are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the Trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error. In preparing the financial statements, the Trustees are responsible for assessing the Charity’s ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Trustees either intend to liquidate the charitable company or to cease operations, or have no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

We have been appointed as auditor under section 144 of the Charities Act 2011 and report in accordance with the Act and relevant regulations made or having effect thereunder.

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

The extent to which our procedures are capable of detecting irregularities, including fraud, is detailed below.

Extent to which the audit was considered capable of detecting irregularities and fraud

Our approach to identifying and assessing the risks of material misstatement in respect of irregularities including fraud and non-compliance with laws and regulations was as follows:

Audit response to risks identified

Docusign Envelope ID: D003D46E-53BD-83B4-8197-501AA7B480EA

LEUKAEMIA CARE

INDEPENDENT AUDITOR'S REPORT (CONTINUED) TO THE TRUSTEES OF LEUKAEMIA CARE

It should be noted that Auditing standards limit the audit procedures required to identify non-compliance with laws and regulations to enquiry of the directors and other management and the inspection of regulatory and legal correspondence, if any.

Our responsibility is to audit and express an opinion on the financial statements in accordance with applicable law and International Standards on Auditing (UK and Ireland). Those standards require us to comply with the Auditing Practices Board's (APB's) Ethical Standard for Auditors, including "APB Ethical Standard - Provisions Available for Small Entities (Revised)", in the circumstances set out in note 29 to the financial statements.

A further description of our responsibilities is available on the Financial Reporting Council’s website at: https:// www.frc.org.uk/auditorsresponsibilities. This description forms part of our auditor's report.

Use of our report

This report is made solely to the charity’s trustees, as a body, in accordance with part 4 of the Charities (Accounts and Reports) Regulations 2008 and regulation 10 of the Charities Accounts (Scotland) Regulations 2006. Our audit work has been undertaken so that we might state to the charity's Trustees those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charity and the charity’s trustees as a body, for our audit work, for this report, or for the opinions we have formed.

Elizabeth Needham ACA CTA (VAT) (Senior Statutory Auditor)

For and on behalf of Kendall Wadley LLP, Statutory Auditor Chartered Accountants Granta Lodge 71 Graham Road Malvern Worcestershire WR14 2JS 24 June 2026

Kendall Wadley LLP is eligible for appointment as auditor of the Charity by virtue of its eligibility for appointment as auditor of a company under section 1212 of the Companies Act 2006.

Docusign Envelope ID: D003D46E-53BD-83B4-8197-501AA7B480EA

LEUKAEMIA CARE

STATEMENT OF FINANCIAL ACTIVITIES INCLUDING INCOME AND EXPENDITURE ACCOUNT FOR THE YEAR ENDED 31 DECEMBER 2025

Current financial year
Unrestricted
Restricted
funds
funds
2025
2025
Notes
£
£
Income and endowments from:
Donations and legacies
3
974,343
291,623
Fundraising income
4
1,152,503
-
Investments
5
76,736
-
Other income
6
1,590
-
Total income
2,205,172
291,623
Expenditure on:
Raising funds
7
859,946
-
Charitable activities
8
1,266,829
322,022
Total expenditure
2,126,775
322,022
Net gains on investments
13
35,276
-
Net income/(expenditure)
113,673
(30,399)
Other recognised gains and losses
Revaluation of tangible fixed assets
-
-
Net movement in funds
113,673
(30,399)
Fund balances at 1 January 2025
2,988,569
223,549
Fund balances at 31 December 2025
3,102,242
193,150		 Total
2025
£
1,265,966
1,152,503
76,736
1,590
2,496,795
859,946
1,588,851
2,448,797
35,276
83,274
-
83,274
3,212,118
3,295,392		 Total
2024
£
1,585,859
1,195,916
38,431
1,493
2,821,699
861,052
1,300,317
2,161,369
46,609
706,939
(67,598)
639,341
2,572,777
3,212,118

Docusign Envelope ID: D003D46E-53BD-83B4-8197-501AA7B480EA

LEUKAEMIA CARE

STATEMENT OF FINANCIAL ACTIVITIES (CONTINUED) INCLUDING INCOME AND EXPENDITURE ACCOUNT FOR THE YEAR ENDED 31 DECEMBER 2025

Prior financial year
Unrestricted
Restricted
funds
funds
2024
2024
Notes
£
£
Income and endowments from:
Donations and legacies
3
1,286,476
299,383
Fundraising income
4
1,195,916
-
Investments
5
38,431
-
Other income
6
1,493
-
Total income
2,522,316
299,383
Expenditure on:
Raising funds
7
861,052
-
Charitable activities
8
1,076,141
224,176
Total expenditure
1,937,193
224,176
Net gains on investments
13
46,609
-
Net income/(expenditure)
631,732
75,207
Other recognised gains and losses
Revaluation of tangible fixed assets
(67,598)
-
Net movement in funds
564,134
75,207
Fund balances on incorporation at 1 January 2024
2,424,435
148,342
Fund balances at 31 December 2024
2,988,569
223,549		 Total
2024
£
1,585,859
1,195,916
38,431
1,493
2,821,699
861,052
1,300,317
2,161,369
46,609
706,939
(67,598)
639,341
2,572,777
3,212,118

Docusign Envelope ID: D003D46E-53BD-83B4-8197-501AA7B480EA

LEUKAEMIA CARE

BALANCE SHEET

AS AT 31 DECEMBER 2025

Notes
Fixed assets
Tangible assets
15
Investments
16
Current assets
Debtors
18
Investments
19
Cash at bank and in hand
Creditors: amounts falling due within
one year
20
Net current assets
Total net assets
Income funds
Restricted funds
22
Unrestricted funds
Designated funds
23
General unrestricted funds		 2025
£
£
778,015
741,728
1,519,743
368,605
1,021,455
515,882
1,905,942
(130,293)
1,775,649
3,295,392
193,150
1,247,757
1,854,485
3,102,242
3,295,392		 2024
£
£
806,869
698,764
1,505,633
332,322
313,222
1,180,908
1,826,452
(119,967)
1,706,485
3,212,118
223,549
1,274,302
1,714,267
2,988,569
3,212,118		 2024
£
£
806,869
698,764
1,505,633
332,322
313,222
1,180,908
1,826,452
(119,967)
1,706,485
3,212,118
223,549
1,274,302
1,714,267
2,988,569
3,212,118
1,505,633
1,706,485
3,212,118
223,549
2,988,569
3,212,118

The company is entitled to the exemption from the audit requirement contained in section 477 of the Companies Act 2006, for the year ended 31 December 2025, although an audit has been carried out under section 144 of the Charities Act 2011.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The members have not required the company to obtain an audit of its financial statements under the requirements of the Companies Act 2006, for the year in question in accordance with section 476.

These financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The financial statements were approved by the Trustees on 24 June 2026

Mr Christopher R. G. Matthews Maxwell (Chair) Trustee

Mrs W J Davies (Treasurer) Trustee

Company Registration No. 11911752

Docusign Envelope ID: D003D46E-53BD-83B4-8197-501AA7B480EA

LEUKAEMIA CARE

STATEMENT OF CASH FLOWS FOR THE YEAR ENDED 31 DECEMBER 2025

Notes
Cash flows from operating activities
Cash (absorbed by)/generated from
operations
29
Investing activities
Purchase of tangible fixed assets
Purchase of other investments
Proceeds on disposal of other investments
Other investment movements
Investment income received
Net cash generated from investing
activities
Net increase in cash and cash equivalents
Cash and cash equivalents at beginning of year
Cash and cash equivalents at end of year
Relating to:
Cash at bank and in hand
Short term deposits included in current
asset investments		 2025
£
£
(18,411)
(7,430)
(89,005)
94,777
(13,460)
76,736
61,618
43,207
1,494,130
1,537,337
515,882
1,021,455		 2024
£
£
638,443
(13,120)
(80,155)
74,539
(309)
38,431
19,386
657,829
836,301
1,494,130
1,180,908
313,222		 2024
£
£
638,443
(13,120)
(80,155)
74,539
(309)
38,431
19,386
657,829
836,301
1,494,130
1,180,908
313,222
657,829
836,301
1,494,130
1,180,908
313,222

Docusign Envelope ID: D003D46E-53BD-83B4-8197-501AA7B480EA

LEUKAEMIA CARE

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2025

1 Accounting policies

Charity information

Leukaemia Care is a private company limited by guarantee incorporated in England and Wales (number: 11911752), a charity registered in England and Wales (number: 1183890) and Scotland (number: SC049802). The address of its registered office is One Birch Court, Blackpole East, Worcester, WR3 8SG.

1.1 Accounting convention

The financial statements have been prepared in accordance with the Charity's governing document, the Charities Act 2011, the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005, the Charities Accounts (Scotland) Regulations 2006 (as amended) and "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019)" and FRS 102. The Charity is a Public Benefit Entity as defined by FRS 102.

The financial statements are prepared in sterling, which is the functional currency of the Charity. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention, modified to include the revaluation of freehold properties and certain financial instruments at fair value. The principal accounting policies adopted are set out below.

Consolidated group financial statements have not been prepared in the current year as the sole subsidiary Leukaemia Care Trading Limited has been excluded from the group accounts. Its inclusion is not material for the purpose of giving a true and fair view due to it being virtually dormant. As the sole subsidiary has been excluded the requirement to prepare consolidated accounts does not apply and hence these are charity only financial statements.

1.2 Going concern

At the time of approving the financial statements, the Trustees have a reasonable expectation that the Charity has adequate resources to continue in operational existence for the foreseeable future and that there are no material uncertainties about its ability to continue. Thus the Trustees continue to adopt the going concern basis of accounting in preparing the financial statements.

1.3 Charitable funds

Unrestricted funds are available for use at the discretion of the Trustees in furtherance of their charitable objectives.

Designated funds comprise funds which have been set aside at the discretion of the Trustees for specific purposes. The purposes and uses of the designated funds are set out in the notes to the financial statements.

Restricted funds are subject to specific conditions by donors or grantors as to how they may be used. The purposes and uses of the restricted funds are set out in the notes to the financial statements.

1.4 Income

Income is recognised when the Charity is legally entitled to it after any performance conditions have been met, the amounts can be measured reliably, and it is probable that income will be received.

Cash donations are recognised on receipt. Other donations are recognised once the Charity has been notified of the donation, unless performance conditions require deferral of the amount. Income tax recoverable in relation to donations received under Gift Aid or deeds of covenant is recognised at the time of the donation.

Grants are recognised once the Charity has been notified, unless performance conditions require deferral of the amount.

Docusign Envelope ID: D003D46E-53BD-83B4-8197-501AA7B480EA

LEUKAEMIA CARE

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2025

1 Accounting policies

(Continued)

Legacies are recognised on receipt or otherwise if the Charity has been notified of an impending distribution, the amount is known, and receipt is expected.

Event income is recognised as income on receipt, as this is when it becomes measurable.

Investment income is included in the SOFA in the year in which it is receivable.

Voluntary income is recognised as income when receivable, except insofar as when it is incapable of financial measurement.

1.5 Expenditure

Expenditure is recognised once there is a legal or constructive obligation to transfer economic benefit to a third party, it is probable that a transfer of economic benefits will be required in settlement, and the amount of the obligation can be measured reliably.

Expenditure is classified by activity. The costs of each activity are made up of the total of direct costs and shared costs, including support costs involved in undertaking each activity. Direct costs attributable to a single activity are allocated directly to that activity. Shared costs which contribute to more than one activity and support costs which are not attributable to a single activity are apportioned between those activities on a basis consistent with the use of resources. Central staff costs are allocated on the basis of time spent, and depreciation charges are allocated on the portion of the asset’s use.

All expenditure is accounted for on an accruals basis, with the exception of expenditure directly attributable to forthcoming events. The income is recognised on receipt and so the expenditure is recognised at point of expense. Costs are allocated to a particular activity where the cost relates to that activity. Costs of generating funds comprise those costs directly attributable to raising funds through activities. Grants payable are recognised on an accruals basis. Salaries and central overhead costs are apportioned between costs of generating funds, charitable activities and governance costs based on estimate of staff time attributable to each.

1.6 Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Freehold buildings over 50 years Computers and other equipment over 3 or 4 years Fixtures and fittings over 10 years

Freehold land is not depreciated.

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is recognised in the statement of financial activities.

The charity has no specific value above which it capitalises assets. Assets are capitalised when they are held for long term use.

Docusign Envelope ID: D003D46E-53BD-83B4-8197-501AA7B480EA

LEUKAEMIA CARE

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2025

1 Accounting policies

(Continued)

1.7 Fixed asset investments

Fixed asset investments are initially measured at transaction price excluding transaction costs, and are subsequently measured at fair value at each reporting date. Changes in fair value are recognised in net income/(expenditure) for the year. Transaction costs are expensed as incurred.

A subsidiary is an entity controlled by the Charity. Control is the power to govern the financial and operating policies of the entity so as to obtain benefits from its activities.

1.8 Impairment of fixed assets

At each reporting end date, the Charity reviews the carrying amounts of its tangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any).

Cash and cash equivalents include cash in hand, deposits held at call with banks and other short-term liquid investments with original maturities of three months or less.

1.10 Current Asset Investments

Current asset investments include deposits with banks and other short-term investments held with the primary intent being to generate investment returns.

1.11 Financial instruments

The Charity has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.

Financial instruments are recognised in the Charity's balance sheet when the Charity becomes party to the contractual provisions of the instrument.

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method. Financial assets classified as receivable within one year are not amortised.

Basic financial liabilities

Basic financial liabilities, including creditors are initially recognised at transaction price. Financial liabilities classified as payable within one year are not amortised.

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of operations from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

Derecognition of financial liabilities

Financial liabilities are derecognised when the Charity’s contractual obligations expire or are discharged or cancelled.

Docusign Envelope ID: D003D46E-53BD-83B4-8197-501AA7B480EA

LEUKAEMIA CARE

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2025

1 Accounting policies

(Continued)

1.12 Employee benefits

The cost of any unused holiday entitlement is recognised in the period in which the employee’s services are received.

Termination benefits are recognised immediately as an expense when the Charity is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

1.13 Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

2 Critical accounting estimates and judgements

In the application of the Charity’s accounting policies, the Trustees are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

Freehold buildings held by the charity were revalued during the prior year, by RICS qualified independent surveyors on a "Red Book" basis. Details of the valuation can be seen in note 15.

3 Income from donations and legacies

Unrestricted
Restricted
funds
funds
2025
2025
£
£
Donations and gifts
227,307
201,466
Legacies
707,375
-
Grants
39,661
90,157
974,343
291,623		 Total
Unrestricted
Restricted
funds
funds
2025
2024
2024
£
£
£
428,773
297,130
197,619
707,375
911,946
-
129,818
77,400
101,764
1,265,966
1,286,476
299,383		 Total
2024
£
494,749
911,946
179,164
1,585,859

4 Income from other trading activities

Unrestricted Unrestricted
funds funds
2025 2024
£ £
Fundraising events 1,152,503 1,195,916

Docusign Envelope ID: D003D46E-53BD-83B4-8197-501AA7B480EA

LEUKAEMIA CARE

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2025

5 Income from investments

Unrestricted Unrestricted
funds funds
2025 2024
£ £
Rental income 17,219 -
Dividends receivable 13,239 11,434
Interest receivable 46,278 26,997
76,736 38,431

6 Other income

Unrestricted Unrestricted
funds funds
2025 2024
£ £
Solar panels 1,590 1,493

7 Raising funds

Unrestricted Unrestricted
funds funds
2025 2024
£ £
Fundraising and publicity
Staging fundraising events 234,483 244,819
Advertising 34,424 16,954
Other fundraising costs 105,104 102,162
Staff costs 390,144 417,651
Depreciation and impairment 4,587 3,334
Investment management fees 5,550 5,514
Support costs (see note 10) 78,777 65,966
Governance costs (see note 10) 6,877 4,652
Fundraising and publicity 859,946 861,052

Docusign Envelope ID: D003D46E-53BD-83B4-8197-501AA7B480EA

LEUKAEMIA CARE

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2025

8 Charitable activities

Staff costs
Depreciation
Patient Services costs
Conferences
Help Line costs
Leukaemia Matters/ Nursing Matters
Campaign costs
Other charitable activities
Nurse e-learning tool
Grants to individuals
Database costs
Patient Advocacy
Website costs
Press
Share of support costs (see note 9)
Share of governance costs (see note 9)
Analysis by fund
Unrestricted funds
Restricted funds		 2025
£
956,982
31,697
148,229
86
2,749
5,016
41,855
4,320
217
96,375
6,283
2,364
68,609
45,373
1,410,155
164,349
14,347
1,588,851
1,266,829
322,022
1,588,851		 2024
£
799,035
22,766
102,686
1,679
4,604
26,100
36,812
6,527
309
119,200
6,611
1,075
19,565
5,629
1,152,598
138,012
9,707
1,300,317
1,076,141
224,176
1,300,317

Docusign Envelope ID: D003D46E-53BD-83B4-8197-501AA7B480EA

LEUKAEMIA CARE

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2025

9 Support costs

Staff costs
Other staff costs
Rent, rates and
insurance
Heat and light
Repairs and renewals
Printing, postage and
stationery
Telephone
Motor and other travel
Subscribtions
Other office costs
Bank charges
Sundry expenses
Audit fees
Legal and professional
Trustee and meeting
expenses
Analysed between
Fundraising
Charitable activities		 Support
costs
Governance
costs
£
£
42,426
-
49,253
-
13,044
-
11,324
-
17,164
-
15,163
-
10,427
-
714
-
4,646
-
50,272
-
1,239
-
27,454
-
-
5,700
-
9,714
-
5,810
243,126
21,224
78,777
6,877
164,349
14,347
243,126
21,224		 2025Support costs Governance
costs
£
£
£
42,426
34,528
-
49,253
23,585
-
13,044
14,566
-
11,324
12,402
-
17,164
19,256
-
15,163
13,031
-
10,427
13,346
-
714
756
-
4,646
2,924
-
50,272
49,914
-
1,239
1,157
-
27,454
18,513
-
5,700
-
5,400
9,714
-
5,128
5,810
-
3,831
264,350
203,978
14,359
85,654
65,966
4,652
178,696
138,012
9,707
264,350
203,978
14,359		 2024
£
34,528
23,585
14,566
12,402
19,256
13,031
13,346
756
2,924
49,914
1,157
18,513
5,400
5,128
3,831
218,337
70,618
147,719
218,337

10 Auditor's remuneration

The analysis of auditor's remuneration is as follows:
Fees payable 2025 2024
£ £
Audit of the annual accounts 5,700 5,400

11 Trustees

The Charity reimburses expenses to Trustees and management committee members for travel, subsistence and telephone relating to charity business. The costs reimbursed to 3 (2024 : 2) trustees for the current year were £5,810 (2024 : £3,831).

None of the Trustees (or any persons connected with them) received any remuneration during the year.

Docusign Envelope ID: D003D46E-53BD-83B4-8197-501AA7B480EA

LEUKAEMIA CARE

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2025

11 Trustees

(Continued)

The charity utilises the services of CKCA Limited to prepare the payroll, W Davies, trustee, is a shareholder of this company. The services are provided on an arms length basis and the amount paid during the year amounted to £2,987 (2024 : £3,045).

All trustees are covered by an indemnity insurance policy costing £921 (2024: £906)

12 Employees

The average monthly number of employees during the year was:

Training and provision of care
Fundraising and publicity
Accounts and administration
Total
Employment costs
Wages and salaries
Social security costs
Other pension costs		 2025
Number
29
14
6
49
2025
£
1,236,159
102,625
50,768
1,389,552		 2024
Number
24
17
5
46
2024
£
1,109,848
95,587
45,779
1,251,214

There were no redundancy or termination payments in the year (2024: £25,484).

The remuneration of key management personnel through payroll and other fees is £230,623 (2024: £191,758).

The number of employees whose annual remuneration was more than £60,000 is as follows:

2025 2024
Number Number
£60,001 to £70,000 - 2
£80,001 to £90,000 1 -

Docusign Envelope ID: D003D46E-53BD-83B4-8197-501AA7B480EA

LEUKAEMIA CARE

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2025

13 Net gains on investments

2025 2024
£ £
Revaluation of investments 35,276 46,609

14 Taxation

There is no taxation payable during the year as the activities undertaken by Leukaemia Care fall within the charitable objectives of the charity.

15 Tangible fixed assets

Cost or valuation
At 1 January 2025
Additions
At 31 December 2025
Depreciation
At 1 January 2025
Depreciation charged in the year
At 31 December 2025
Carrying amount
At 31 December 2025
At 31 December 2024		 Freehold
buildings
Computers
and other
equipment
Fixtures and
fittings
£
£
£
775,000
108,192
14,656
-
7,430
-
775,000
115,622
14,656
-
76,639
14,340
15,500
20,619
165
15,500
97,258
14,505
759,500
18,364
151
775,000
31,553
316		 Total
£
897,848
7,430
905,278
90,979
36,284
127,263
778,015
806,869

Land and buildings with a carrying amount of £759,500 were revalued at 2 July 2024 by Clarke & Jay Chartered Surveyors, independent valuers not connected with the Charity. The valuation conforms to RICS Valuation - Global Standards 2022 - "Red Book" and was based on current market valuation.

At 31 December 2025, had the revalued assets been carried at historic cost less accumulated depreciation and accumulated impairment losses, their carrying amount would have been approximately £842,599 (2024: £842,599).

Docusign Envelope ID: D003D46E-53BD-83B4-8197-501AA7B480EA

LEUKAEMIA CARE

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2025

16 Fixed asset investments

Listed
investments
Cash in
portfolio
Other
investments
£
Cost or valuation
At 1 January 2025
689,390
9,274
100
Additions
89,005
(89,005)
-
Valuation changes
35,276
-
-
Other cash movements
-
7,688
-
Disposals
(94,777)
94,777
-
At 31 December 2025
718,894
22,734
100
Carrying amount
At 31 December 2025
718,894
22,734
100
At 31 December 2024
689,390
9,274
100
2025
Other investments comprise:
Notes
£
Investments in subsidiaries
27
100
17
Financial instruments
2025
£
Carrying amount of financial assets
Instruments measured at fair value through profit or loss
718,894
18
Debtors
2025
Amounts falling due within one year:
£
Trade debtors
10,655
Amounts owed by subsidiary undertakings
4,135
Other debtors
-
Prepayments and accrued income
353,815
368,605		 Total
£
698,764
-
35,276
7,688
-
741,728
741,728
698,764
2024
£
100
2024
£
689,390
2024
£
51,994
2,084
300
277,944
332,322

Docusign Envelope ID: D003D46E-53BD-83B4-8197-501AA7B480EA

LEUKAEMIA CARE

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2025

19
Current asset investments
Term deposits
20
Creditors: amounts falling due within one year
Other taxation and social security
Trade creditors
Other creditors
Accruals
21
Retirement benefit schemes
Defined contribution schemes
Charge to profit or loss in respect of defined contribution schemes		 2025
£
1,021,455
2025
£
31,157
24,444
11,818
62,874
130,293
2025
£
50,768		 2024
£
313,222
2024
£
26,833
23,486
-
69,648
119,967
2024
£
45,779

The Charity operates a defined contribution pension scheme for all qualifying employees. The assets of the scheme are held separately from those of the Charity in an independently administered fund.

Docusign Envelope ID: D003D46E-53BD-83B4-8197-501AA7B480EA

Restricted funds The restricted funds of the charity comprise the unexpended balances of donations and grants held on trust subject to specific conditions by donors as to how they may be used. Movement in funds
Movement in funds		 Balance at 1
Income
Expenditure
Balance at
Income
Expenditure
Balance at		 January 2024
1 January 2025
31 December		 2025 £
£
£
£
£
£
£		 Information Booklets
5,985
27,575
(33,120)
440
38,075
(38,515)
-		 Nurse Advisor
-
45,764
(8,452)
37,312
38,282
(54,313)
21,281		 Glasgow Area
2,829
5,600
(6,396)
2,033
1,500
(3,533)
-		 Support Group - Scotland
2,578
-
(1,080)
1,498
-
-
1,498		 Support Group - Leicestershire
3,115
500
-
3,615
-
-
3,615		 Belfast Hospital Support
11,999
3,000
(8,325)
6,674
-
(6,674)
-		 Bristol Hospital Support
406
6,062
(6,468)
-
3,000
(3,000)
-		 Financial Grants
-
30,000
(30,000)
-
-
-
-		 Buddy Scheme
-
20,000
(12,330)
7,670
20,200
(27,870)
-		 West Midlands Hospital Support
-
29,000
(12,497)
16,503
31,785
(14,977)
33,311		 Spot Leukaemia
-
15,000
(15,000)
-
-
-
-		 Newcastle Hospital Support
4,306
7,800
(7,994)
4,112
2,000
(6,112)
-		 Manchester Hospital Support
2,830
6,125
(6,418)
2,537
2,375
(4,912)
-		 Nottingham Hospital Support
11,454
2,500
(4,210)
9,744
3,500
(8,490)
4,754		 Patient Support Scotland
1,706
-
(750)
956
-
(525)
431		 William Davidson - Aberdeen Area
33,528
-
(300)
33,228
-
(525)
32,703		 Yorkshire Patient Support
3,736
-
(353)
3,383
-
(3,383)
-		 Wales Hospital Support
3,611
31,680
(7,166)
28,125
(3,983)
(8,924)
15,218		 Oxfordshire Hospital Support
2,000
1,000
-
3,000
-
-
3,000		 Support Group Leeds
1,040
-
(432)
608
-
(608)
-		 Carried forward
91,123
231,606
(161,291)
161,438
136,734
(182,361)
115,811
22

Docusign Envelope ID: D003D46E-53BD-83B4-8197-501AA7B480EA

(Continued) 115,811 13,430 31,628 14,889 - - 6,000 633 - - 4,166 5,293 1,000 - - 300 - - - 193,150
(182,361) (15,570) (8,750) (8,628) (1,458) (1) - (8,143) (3,000) (156) (10,499) (6,309) - (6,447) (1,500) (500) (20,000) (46,200) (2,500) (322,022)
136,734 22,000 29,689 12,500 - - - 5,000 - - 10,000 5,500 - - 1,500 - 20,000 46,200 2,500 291,623
161,438 7,000 10,689 11,017 1,458 1 6,000 3,776 3,000 156 4,665 6,102 1,000 6,447 - 800 - - - 223,549
(161,291) - - (5,895) (7,591) (7,789) - (4,224) - (756) (9,981) (5,398) - (9,553) (7,184) (450) (4,064) - - (224,176)
231,606 - 8,189 9,300 - 5,790 - - - - 7,500 8,500 - 16,000 7,184 1,250 4,064 - - 299,383
91,123 7,000 2,500 7,612 9,049 2,000 6,000 8,000 3,000 912 7,146 3,000 1,000 - - - - - - 148,342
Restricted funds Brought forward Glasgow Hospital Support Northern Ireland Hospital Support NNUH Hospital Support Plymouth/Devon Cambridge Merseyside Swindon Hospital Support Guy's & St Thomas Hospital Support Support Group Manchester Dorset (Bournemouth) Brighton Aberdeen Southhampton Hospital Support Leeds Hospital Support Patient Support Reading Hospital Hubs Website Leicester Hospital Support
22

Docusign Envelope ID: D003D46E-53BD-83B4-8197-501AA7B480EA

Restricted funds
(Continued)		 Information booklets: funds received to assist in the production of information booklets. Nurse Advisor - in support of the Nurse Advisor services. Glasgow Area - funds to support services in the Glasgow area. Support Group Scotland - to facilitate activities for the groups in Scotland. Support Group Leicestershire - to facilitate activities for support groups in these areas. Belfast Hospital Support - in support of the costs in providing ward support. Bristol Hospital Support - in support of the costs in providing ward support. Financial Grants - This fund is designed to help with the financial strain that can come with a blood cancer diagnosis and treatment, providing practical help with Financial Grants - This fund is designed to help with the financial strain that can come with a blood cancer diagnosis and treatment, providing practical help with everyday costs related to the illness. Buddy Scheme - one to one support for patients. West Midlands Hospital Support -to facilitate activities for local support groups. Spot Leukaemia - to raise awareness of signs and symptoms of Leukaemia. Newcastle Hospital Support - in support of costs in providing ward support. Manchester Hospital Support - in support of costs in providing ward support. Nottingham Hospital Support - in support of costs in providing ward support. Patient Support Scotland - to facilitate activities and support in this area. Patient Support Scotland - to facilitate activities and support in this area. William Davidson - Aberdeen Area - to facilitate activities and support in this area. Yorkshire Support - to facilitate activities and support in this area.Wales Hospital Support - in support of costs in providing ward support. Yorkshire Support - to facilitate activities and support in this area.Wales Hospital Support - in support of costs in providing ward support. Wales Hospital Support - in support of costs in providing ward support. Oxfordshire Hospital Support - in support of costs in providing ward support. Support Group Leeds – to facilitate activities for support groups in this area. Glasgow Hospital Support - in support of costs in providing ward support. Northern Ireland Hospital Support - in support of costs in providing ward support. NNUH Hospital Support - in support of costs in providing ward support. Plymouth/Devon – to facilitate activities and support in this area. Cambridge - to facilitate activities and support in this area. Merseyside - to facilitate activities and support in this area. Swindon Hospital Support - in support of costs in providing ward support. Guy’s & St Thomas’ Hospital Support - in support of costs in providing ward support. Support Group Manchester - to facilitate activities for support groups in this area. Dorset - to facilitate activities and support in this area. Brighton - in support of costs in providing ward support. Aberdeen - to facilitate activities and support in this area. Southhampton Hospital Support - in support of costs in providing ward support. Leeds Hospital Support - in support of costs in providing ward support.
22

Docusign Envelope ID: D003D46E-53BD-83B4-8197-501AA7B480EA

Docusign Envelope ID: D003D46E-53BD-83B4-8197-501AA7B480EA

LEUKAEMIA CARE

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2025

23 Designated funds

The unrestricted funds of the charity comprise the unexpended balances of donations and grants which are not subject to specific conditions by donors and grantors as to how they may be used. These include designated funds which have been set aside out of unrestricted funds by the trustees for specific purposes.

Balance at 1
January 2024
£
Fixed asset fund
887,448
Strategic implementation
fund
227,528
1,114,976		 Transfers
Balance at
1 January 2025
£
£
(80,579)
806,869
239,905
467,433
159,326
1,274,302		 Resources
expended
£
(36,284)
-
(36,284)		 Transfers
Balance at
31 December
2025
£
£
7,430
778,015
2,309
469,742
9,739
1,247,757		 Transfers
Balance at
31 December
2025
£
£
7,430
778,015
2,309
469,742
9,739
1,247,757
1,247,757

Fixed assets fund: The Trustees have agreed to assign all tangible fixed assets held with the exception of any which have restrictions imposed upon them to a general fixed asset designated fund. This was done to ensure that the Charity will have suitable levels of reserves to meet future depreciation costs relating to these fixed assets and to recognise the fact that future depreciation charges will not directly affect the net operating capital of the Charity.

Strategic Implementation Fund: funds to support the delivery of strategy adopted by the Board of Trustees.

Docusign Envelope ID: D003D46E-53BD-83B4-8197-501AA7B480EA

Total 2024 £ 806,869 698,764 1,706,485 3,212,118
Restricted funds 2024 £ - - 223,549 223,549
Designated funds 2024 £ 806,869 - 467,433 1,274,302
Total Unrestricted funds 2025
2024		 £
£		 778,015
-		 741,728
698,764		 1,775,649
1,015,503		 3,295,392
1,714,267
Restricted funds 2025 £ - - 193,150 193,150
Designated funds 2025 £ 778,015 - 469,742 1,247,757
Unrestricted funds 2025 £ - 741,728 1,112,757 1,854,485
Analysis of net assets between funds Fund balances are represented by: Tangible assets Investments Current assets/(liabilities)
24

Docusign Envelope ID: D003D46E-53BD-83B4-8197-501AA7B480EA

LEUKAEMIA CARE

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2025

25 Capital commitments 2025 2024
£ £
Amounts contracted for but not provided in the financial statements:
2025 2024
£ £
Acquisition of property, plant and equipment 83,506 -

26 Related party transactions

There were no disclosable related party transactions during the year (2024 - none) other than as disclosed in note 11.

27 Subsidiaries

These financial statements are separate Charity financial statements for Leukaemia Care.

Details of the Charity's subsidiaries at 31 December 2025 are as follows:

Name of undertaking Registered Nature of business Class of % Held
office shares held Direct Indirect
Leukaemia Care Trading England Unicorn walk Ordinary 100.00
Limited

The aggregate capital and reserves and the result for the year was as follows:

Name of undertaking Profit/(Loss) Capital and
Reserves
£ £
Leukaemia Care Trading
Limited (521) (206,300)

28 Analysis of changes in net funds

The Charity had no material debt during the year.

Docusign Envelope ID: D003D46E-53BD-83B4-8197-501AA7B480EA

LEUKAEMIA CARE

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2025

29
Cash generated from operations
Surplus for the year
Adjustments for:
Investment income recognised in statement of financial activities
Fair value gains and losses on investments
Depreciation and impairment of tangible fixed assets
Movements in working capital:
(Increase)/decrease in stocks
(Increase) in debtors
Increase in creditors
Cash (absorbed by)/generated from operations		 2025
£
83,274
(76,736)
(35,276)
36,284
-
(36,283)
10,326
(18,411)		 2024
£
706,939
(38,431)
(46,609)
26,101
8,435
(30,520)
12,528
638,443

30 Provisions available for small entities

We have taken the exemption permitted by "APB Ethical Standard - Provisions Available for Small Entities (Revised)" to mitigate the management threat in relation to the non-audit service of preparing the statutory accounts.